COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A multi-center single arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Dual CD20 and CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Principal Investigator
Nirav Shah
Phase
II
Summary
Evaluate the effects of an investigational cell and gene treatment called MB-CART2019.1 on the cancer cells in patients who have relapsed (responded to treatment but then returns) and/or refractory (has not responded to initial treatment) DLBCL.
Description
Phase II MB-CART2019.1 for R/R DLBCL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL